Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 172

1.

[Progestational agents and bone metastasis in breast cancer].

Leriche N, Bonneterre J.

Bull Cancer. 1997 Sep;84(9):891-4. French.

2.

Progestins in breast cancer treatment. A review.

Lundgren S.

Acta Oncol. 1992;31(7):709-22. Review.

PMID:
1476750
3.

Oral high-dose medroxyprogesterone acetate versus tamoxifen. A randomized crossover trial in postmenopausal patients with advanced breast cancer.

van Veelen H, Willemse PH, Tjabbes T, Schweitzer MJ, Sleijfer DT.

Cancer. 1986 Jul 1;58(1):7-13.

PMID:
2939943
4.

A randomized comparison of megestrol acetate (MA) and medroxyprogesterone acetate (MPA) in patients with advanced breast cancer.

Willemse PH, van der Ploeg E, Sleijfer DT, Tjabbes T, van Veelen H.

Eur J Cancer. 1990 Mar;26(3):337-43.

PMID:
2141491
5.

Randomized trial comparing aminoglutethimide with high-dose medroxyprogesterone acetate in therapy for advanced breast carcinoma.

Canney PA, Priestman TJ, Griffiths T, Latief TN, Mould JJ, Spooner D.

J Natl Cancer Inst. 1988 Sep 21;80(14):1147-51.

PMID:
2970555
6.

[2d and 3d line hormonal therapy in postmenopausal metastatic breast tumor. Comparison of medroxyprogesterone acetate and aminoglutethimide in tamoxifen-resistant patients].

Garcia-Giralt E, Omodei Zorini C, Ferri L, Ayme Y, Carton M, Daban A, Delozier T, Fargeot P, Fumoleau P, Gorins A, et al.

Clin Ter. 1994 Aug;145(8):113-21. Italian.

PMID:
7955956
7.

[Results of tamoxifen-medroxyprogesterone acetate sequential therapy in 22 patients with recurrent breast cancer].

Noguchi S, Yamamoto H, Inaii H, Koyama H.

Gan To Kagaku Ryoho. 1989 Nov;16(11):3555-8. Japanese.

PMID:
2530936
8.

Randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer.

Lipton A, Harvey HA, Santen RJ, Boucher A, White D, Bernath A, Dixon R, Richards G, Shafik A.

Cancer Res. 1982 Aug;42(8 Suppl):3434s-3436s.

9.

Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate: its correlation with serum cortisol.

Van Deijk WA, Blijham GH, Mellink WA, Meulenberg PM.

Cancer Treat Rep. 1985 Jan;69(1):85-90.

PMID:
3155651
10.

The role of tamoxifen and aromatase inhibitors/inactivators in postmenopausal patients.

Pritchard KI.

Clin Cancer Res. 2001 Dec;7(12 Suppl):4356s-4359s; discussion 4411s-4412s. Review.

PMID:
11916225
11.

Aromatase inhibitors in post-menopausal metastatic breast carcinoma.

Carlini P, Bria E, Giannarelli D, Felici A, Papaldo P, Fabi A, Ruggeri EM, Milella M, Nuzzo C, Cecere FL, Gelibter A, Pino MS, Nisticò C, Cuppone F, Metro G, Terzoli E, Cognetti F, Ferretti G.

Expert Opin Investig Drugs. 2007 Jul;16(7):1023-36. Review.

PMID:
17594187
13.

Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.

Mauri D, Pavlidis N, Polyzos NP, Ioannidis JP.

J Natl Cancer Inst. 2006 Sep 20;98(18):1285-91.

PMID:
16985247
14.

[A case of disseminated breast cancer successfully treated with medroxyprogesterone acetate].

Tsumura I, Okamura Y, Takatsuka Y, Kobayakawa K, Kawahara T.

Gan To Kagaku Ryoho. 1990 Aug;17(8 Pt 1):1509-12. Japanese.

PMID:
2143889
15.

Maintenance treatment with medroxyprogesterone acetate in patients with advanced breast cancer responding to chemotherapy: results of a randomized trial. Essen Breast Cancer Study Group.

Kloke O, Klaassen U, Oberhoff C, Hartwich G, Szanto J, Wolf E, Heckmann M, Huhn R, Stephan L, Schnepper U, Donsbach GM, Bechtel C, Rudolph R, Berke A, Borquez D, Hawig I, Hirche H, Schindler AE, Seeber S, Becher R.

Breast Cancer Res Treat. 1999 May;55(1):51-9.

PMID:
10472779
16.

[A case of breast cancer with metastasis of multiple organs showing marked efficacy of medroxyprogesterone acetate (MPA)].

Shimada K, Karaki Y, Ansai Y, Hino K, Yamashita Y, Fujimaki M.

Gan To Kagaku Ryoho. 1996 Apr;23(5):623-6. Japanese.

PMID:
8678522
18.

Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.

Cohen MH, Johnson JR, Li N, Chen G, Pazdur R.

Clin Cancer Res. 2002 Mar;8(3):665-9.

19.

Prognostic value of plasma prostate specific antigen after megestrol acetate treatment in patients with metastatic breast carcinoma.

Diamandis EP, Helle SI, Yu H, Melegos DN, Lundgren S, Lonning PE.

Cancer. 1999 Feb 15;85(4):891-8.

PMID:
10091767
20.

Effects of antiestrogen and progestin on immune functions in breast cancer patients.

Scambia G, Panici PB, Maccio A, Castelli P, Serri F, Mantovani G, Massidda B, Iacobelli S, Del Giacco S, Mancuso S.

Cancer. 1988 Jun 1;61(11):2214-8.

PMID:
2966668

Supplemental Content

Support Center